Oncotelic Research Highlights Context-Dependent Biomarkers in Cancer

Event summary

  • Oncotelic Therapeutics and the Brush and Key Foundation published a peer-reviewed study in the International Journal of Molecular Sciences on December 15, 2025.
  • The study analyzed data from over 7,000 patients with hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC).
  • The research focused on the prognostic significance of biomarkers DNMT3A and GMPS, demonstrating their context-dependent nature.
  • Drashya Shah, an intern supported by the Brush and Key Foundation, was a key author of the publication.

The big picture

The publication underscores the growing recognition that biomarker interpretation requires a nuanced understanding of the tumor microenvironment, moving beyond simplistic, isolated measurements. This research highlights the challenges in translating biomarker discoveries into actionable clinical tools, particularly in complex cancers like HCC and PDAC, which collectively represent a significant unmet medical need. The collaboration between Oncotelic and a non-profit foundation also points to a potential model for resource-constrained biotech companies to advance research.

What we're watching

Clinical Translation
The findings regarding context-dependent biomarkers may complicate clinical application and require further refinement of diagnostic and therapeutic strategies for HCC and PDAC.
Foundation Impact
The Brush and Key Foundation's model of mentorship and research support could become a more common approach for smaller biotech firms seeking to accelerate scientific output.
Biomarker Validation
The study's conclusions regarding DNMT3A and GMPS will need to be validated in larger, independent cohorts to confirm the findings and assess their clinical utility.

Related topics

Biotechnology